Skip to main content

Table 1 Baseline demographic and disease characteristics in all systemic JIA CTP patients

From: Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans

 

GC (N = 2)

MTX (N = 6)

IL1 Inhibitor (N = 12)

IL6 Inhibitor (N = 10)

Total (N = 30)

P-value

Age in yearsa

12.8

3.4

4.0

9.8

5.7

0.047

Female

50%

67%

92%

90%

83%

0.3

White

0%

83%

33%

80%

57%

0.03

Disease duration (days)a

121

38

31

55

42.5

0.2

Polyarthritis

0%

50%

67%

80%

63%

0.18

Number of active jointsa

1.0

4.5

5.0

5.5

4.0

0.28

ESR >3x ULN

100%

67%

91%

43%

73%

0.27

CRP >3x ULN

100%

83%

91%

40%

79%

0.28

Ferritin (ng/mL)a

12,874

1,394

1,062

627

783

0.09

CHAQ scorea

0.9

1.3

1.9

0.8

1.4

0.6

Pain score (0–10)a

3

6.5

6

7.5

6

0.6

Physician global assessment (0–10)a

4

7

5

5

5.5

0.12

Parent global assessment well-being (0–10)a

0

7

6

6

6

0.103

Initiated GC at baseline

100%

100%

42%

70%

67%

0.029

Initial GC dose (mg/kg)a

0.67

0.97

0.00

0.68

0.80

0.548

GC prior to baseline

50%

16.7%

8.3%

30%

20%

0.350

Initial dose of each CTP medication in mg/kg (IQR)a

0.67 (0.6–0.73)

0.487 (0.46–0.64)

2.93 (2–3.6)b

8.14 (8–12)

Not Applicable

 
  1. aMedian
  2. bAnakinra dose (anakinra was used as the initial IL-1i in all patients)